Auto-immune

Delve into the world of Auto-immune in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Auto-immune to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers
CompanyDrug

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that the first patient has been dosed in its Phase I/II clinical trial of APL‑2501 in patients with advanced solid tumors. APL‑2501…

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
CompanyDrug

Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101

EMA's CHMP Supports Approval of Eli Lilly's Omvoh (Mirikizumab) for Crohn's Disease
CompanyDrug

EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
CompanyDrug

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH

InventisBio's Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
CompanyDrug

InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China
CompanyDeals

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
CompanyDrug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
CompanyDrug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

Show More